TORONTO, May 11, 2022
/CNW/ - CareRx Corporation ("CareRx" or the "Company") (TSX:
CRRX), Canada's leading provider
of pharmacy services to seniors living and other congregate care
communities, today reported its financial results for the first
quarter ended March 31, 2022.
Highlights for the First Quarter of 2022
(All percentage increases are as compared to the first quarter
of 2021)
- Revenue increased 108% to $93.2
million from $44.9
million:
-
- Growth driven primarily by contribution from the prior year
acquisitions of SmartMeds, Rexall LTC Pharmacy and Medical
Pharmacies Group Limited LTC Pharmacy ("MPGL LTC Pharmacy", and
collectively, the "Acquired Businesses") as well as organic growth
from contracts that were onboarded throughout 2021.
- Adjusted EBITDA1 increased 111% to $8.6 million from $4.1
million:
-
- Growth driven primarily by contributions of the Acquired
Businesses, as well as from new contracts that were onboarded
throughout 2021.
- Net loss decreased by 53% to $2.8
million from $5.9
million:
-
- Decrease in net loss was driven primarily by the contribution
of the Acquired Businesses and non-cash adjustments related to the
change in fair value of derivative financial instruments partially
offset by an increase in transaction and restructuring costs
related to the transition and integration of the MPGL LTC Pharmacy
Business and an increase in share-based compensation.
- Continued integration of MPGL LTC Pharmacy Business as
planned:
-
- Total cumulative cost savings synergies realized by the end of
the first quarter of 2022 were approximately $0.5 million, or $2.0
million annualized, with total annual cost savings synergies
of approximately $5.0 million
expected to be realized upon the completion of the
integration;
- One pharmacy site was consolidated during the first quarter of
2022 with three additional consolidations expected to be completed
in 2022 and the last remaining site consolidation now expected in
the first half of 2023; and
- Integration projects otherwise expected to be substantially
complete by the end of the third quarter of 2022.
- Secured long-term extensions with three of the Company's four
largest customers, including its two largest customers,
representing approximately 18,000 total beds serviced, for an
average of 5.5 years from the end of 2021.
- Expected to offboard approximately 5,800 beds throughout the
second half of 2022 as a result of a large customer awarding a
request for proposal to another pharmacy services provider.
- Entered into a definitive agreement to acquire the Long-Term
Care Pharmacy Business ("Hogan LTC Pharmacy") of Hogan Pharmacy
Partners Ltd. ("Hogan"):
-
- Currently serving approximately 725 residents in long-term care
and retirement homes in Ontario
and expected to contribute run-rate annualized revenue and Adjusted
EBITDA1 of approximately $4.0
million and $0.6 million,
respectively, not including potential cost savings synergies;
and
- The Company will sign a new seven-year contract with Hogan's
largest customer, a regional seniors living operator, representing
approximately 85% of the beds serviced by Hogan. Hogan's customers
are expected to increase their beds serviced by over 1,200 beds by
the fourth anniversary of closing based on new license allocations
and other anticipated growth plans, which is expected to increase
the total beds serviced to approximately 2,000.
- Ontario Ministry of Health announced that it postponed
previously scheduled changes to long-term care pharmacy funding for
a further year.
- Expanded scope of medical supplies business under new brand,
Revicare™, offering significantly increased assortment of medical
supplies.
Highlights Subsequent to the End of the First Quarter of
2022
- Commenced operations in April at new innovative high-volume
fulfillment centre in Oakville,
Ontario
-
- New fulfillment centre will allow for enhanced operating
margins through higher prescription volumes without additional
labour costs, while improving safety and reducing medication
packaging errors and waste; and
- Will be the first pharmacy in Canada to use BD RowaTM Dose
medication packaging system from Becton, Dickinson and Company
which will optimize the high-volume dispensing of medications at
speeds that exceed conventional packaging solutions currently
utilized in Canada.
- Further pricing adjustments under the agreement between the
pan-Canadian Pharmaceutical Alliance (the "pCPA") and the Canadian
Generic Pharmaceutical Association (the "CGPA"), with the gross
impact of the announced pricing changes expected to be a reduction
to Adjusted EBITDA1 of approximately $0.5 million for 2022.
- Appointed Maria Perrella as an
independent member of the Company's Board of Directors.
1 See "Non-IFRS Measures"
below.
"The first quarter of 2022 once again saw strong year-over-year
revenue and Adjusted EBITDA growth, driven by both acquisitions and
organic growth, and by continued outstanding execution by our
team," said David Murphy, President
and Chief Executive Officer of CareRx. "We delivered a solid start
to 2022, despite average bed count for the quarter being slightly
dampened by the impact of the Omicron variant. Importantly, during
the quarter we continued to execute in areas that will support our
growth in the near- and long-terms. The integration of MPGL
continues to steadily progress and is on track to be substantially
completed by the third quarter of this year. We also announced our
fifth acquisition in the past two years, entering into a definitive
agreement to acquire Hogan Long-Term Care Pharmacy to continue to
expand our industry leading technology and service offering."
FINANCIAL RESULTS
Selected Financial Information
|
For the three month
periods ended March 31,
|
(Thousands of
Canadian dollars except per
share amounts and percentages)
|
2022
|
2021
|
2020
|
$
|
$
|
$
|
Revenue
|
93,176
|
44,857
|
30,426
|
|
|
|
|
EBITDA1
|
5,521
|
(101)
|
(261)
|
Adjusted
EBITDA1
|
8,616
|
4,086
|
2,045
|
Per share -
Basic
|
$0.19
|
$0.15
|
$0.14
|
Per share -
Diluted
|
$0.19
|
$0.15
|
$0.08
|
Adjusted EBITDA
Margin1
|
9.2%
|
9.1%
|
6.7%
|
|
|
|
|
|
|
|
|
Net income
(loss)
|
(2,762)
|
(5,866)
|
5,314
|
Per share -
Basic
|
($0.06)
|
($0.21)
|
$0.37
|
Per share -
Diluted
|
($0.06)
|
($0.21)
|
$0.21
|
|
|
|
|
Cash used in
operations
|
(1,176)
|
(1,705)
|
(1,450)
|
|
|
|
|
Total
Assets
|
285,041
|
170,624
|
92,566
|
Total
Liabilities
|
203,247
|
143,934
|
105,163
|
1 See
"Non-IFRS Measures" below.
|
Non-IFRS Measures
This press release includes certain measures which have not been
prepared in accordance with IFRS such as "EBITDA", "Adjusted
EBITDA", "Adjusted EBITDA Margin" and "Adjusted EBITDA per share".
These non-IFRS measures are not recognized under IFRS and,
accordingly, shareholders are cautioned that these measures should
not be construed as alternatives to net income determined in
accordance with IFRS. The non-IFRS measures presented are unlikely
to be comparable to similar measures presented by other
issuers.
The Company defines "EBITDA" as earnings before depreciation and
amortization, finance costs (income), net, and income tax expense
(recovery). "Adjusted EBITDA" is defined as EBITDA before
transaction and restructuring costs, change in fair value of
contingent consideration liability, impairments, change in fair
value of derivative financial instruments, change in fair value of
investment, gain on disposal of property and equipment and
stock-based compensation expense. "Adjusted EBITDA Margin" is
defined as Adjusted EBITDA divided by revenue. "Adjusted EBITDA per
share" is defined as Adjusted EBITDA divided by the weighted
average outstanding shares on both a basic and diluted basis. The
Company believes that Adjusted EBITDA is a meaningful financial
metric as it measures cash generated from operations which the
Company can use to fund working capital requirements, service
interest and principal debt repayments and fund future growth
initiatives. The Company's agreements with lenders are also
structured with certain financial performance covenants which
includes Adjusted EBITDA as a key component of the covenant
calculation. EBITDA and Adjusted EBITDA are not recognized measures
under IFRS.
Reconciliation of Non-IFRS Measures
|
For the three month
periods ended
March 31,
|
|
2022
|
2021
|
(Thousands of
Canadian Dollars except per share amounts)
|
$
|
$
|
|
|
|
Net
loss
|
(2,762)
|
(5,866)
|
Depreciation and
amortization
|
4,699
|
3,092
|
Finance costs,
net
|
3,674
|
3,421
|
Income tax
recovery
|
(90)
|
(748)
|
EBITDA
|
5,521
|
(101)
|
Transaction and
restructuring costs
|
2,688
|
767
|
Change in fair value of
contingent consideration liability
|
96
|
169
|
Share-based
compensation expense
|
1,330
|
753
|
Change in fair value of
derivative financial instruments
|
(1,126)
|
2,605
|
(Gain) loss on disposal
of assets
|
107
|
(107)
|
Adjusted
EBITDA
|
8,616
|
4,086
|
|
|
|
Weighted average number
of shares - basic and diluted (in thousands)
|
46,504
|
28,048
|
Adjusted EBITDA per
share - basic and diluted
|
$0.19
|
$0.15
|
Conference Call
The Company will host a conference call, including a slide
presentation, to discuss its first quarter 2022 financial results
on Thursday, May 12, 2022 at
8:30 a.m. Eastern Time (ET).
Telephone Dial-In Access Information
To access the conference call by telephone, dial 647-484-0475 or
1-888-220-8451. Please connect approximately 15 minutes prior to
the beginning of the call to ensure participation. Those
participating in the conference call by telephone can view the
slide presentation by accessing the online webcast (see
instructions below) and choosing the Non-Streaming Audio
option.
Webcast Access Information
A live webcast of the conference call, including the slide
presentation, will be available on the Events and Presentations
page of the Investors section of the Company's website
(https://carerx.ca/presentations/). Please connect at least 15
minutes prior to the conference call to ensure adequate time for
any software download that may be required to join the webcast. To
view the webcast presentation with slides, please choose either the
Real Streaming Audio or Windows Streaming Audio option.
The webcast with slide presentation will be archived for 90 days
on the Events and Presentations page of the Investors section of
the Company's website (https://carerx.ca/presentations/).
About CareRx Corporation
CareRx is Canada's leading
provider of pharmacy services to seniors living communities. We
serve over 95,000 residents in over 1,600 seniors and other
congregate care communities (long-term care homes, retirement
homes, assisted living facilities, and group homes). We are a
national organization with a large network of pharmacy fulfillment
centres strategically located across the country. This allows us to
deliver medications in a timely and cost-effective manner and
quickly respond to routine changes in medication management. We use
best-in-class technology that automates the preparation and
verification of multi-dose compliance packaging of medication,
providing the highest levels of safety and adherence for
individuals with complex medication regimes. We take an active role
in working with our home operator partners to promote resident
health, staff education, and medication system quality and
efficiency.
Forward-Looking Statements
This press release contains statements that may constitute
"forward-looking statements" within the meaning of applicable
Canadian securities legislation. These forward-looking statements
include, among others, statements regarding the Company's business
strategy, plans and other expectations, beliefs, goals, objectives,
information and statements about possible future events.
Forward-looking statements generally can be identified by the use
of forward-looking terminology such as "may", "will", "expect",
"intend", "estimate", "anticipate" or similar expressions
suggesting future outcomes or events. Such forward-looking
statements reflect management's current beliefs and are based on
information currently available to management.
Forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from those
contemplated by such statements. Factors that could cause such
differences include the Company's exposure to and reliance on
government regulation and funding, the Company's liquidity and
capital requirements, exposure to epidemic or pandemic outbreak,
the highly competitive nature of the Company's industry, reliance
on contracts with key customers and other risk factors described
from time to time in the reports and disclosure documents filed by
the Company with Canadian securities regulatory agencies and
commissions. These and other factors should be considered carefully
and readers should not place undue reliance on the Company's
forward-looking statements. As a result of the foregoing and other
factors, no assurance can be given as to any such future results,
levels of activity or achievements and neither the Company nor any
other person assumes responsibility for the accuracy and
completeness of these forward-looking statements. The factors
underlying current expectations are dynamic and subject to
change.
SOURCE CareRx Corporation